AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio

Key TakeawaysAbbVie reported strong sales of its other medicines as demand for Humira fell because of competition from biosimilar drugs.Revenue from rheumatoid arthritis medicines Rinvoq and Skyrizi soared.The news sent AbbVie shares to an all-time high in intraday trading Thursday. AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Humira sales. The company repo ...